Allgenesis Biotherapeutics Inc.

Ap Biosciences Inc.

Pei-Tzu Wu

Tan Nguyen

Kevin Zen

Yung-Sheng Chang

Madhu Cherukury

Jia-Hau Shiu

Jeng-Horng Her

Huang-Tsu Chen

Ching-Hsuan Hsu

Jiun-Shyang Leou

The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway as well as formulation compositions of such fusion proteins, as well as methods for producing and using the same.

VEGFR fusion protein pharmaceutical composition

The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.

Fusion proteins for inhibiting angiogenesis

Fusion proteins containing a PDGF binding portion, a VEGF binding portion, and an Fc antibody region are described. Also described are nucleic acids encoding the fusion proteins, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing clinical conditions characterized by abnormal angiogenesis, such as vascular permeability, edema or inflammation.

Fusion protein comprising a ligand binding domain of VEGF and PDGF

Growing community of inventors

Taipei, Taiwan

Pei-Tzu Wu